secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001787306-23-000042
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds
-----------------------------------------------------------------------------

- Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.
- Net loss $80.1M ($1.31/share) vs $64.3M ($1.27) in Q1 2022; SG&A rose to $42.9M.
- Cash, equivalents, and marketable securities $333.3M; operating cash burn $80.3M in Q1.
- Health Canada approved ZORYVE for plaque psoriasis; launch expected in coming weeks.
- FDA accepted NDA for roflumilast foam (seborrheic dermatitis); target action date Dec 16, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/0001787306-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000042/arqt-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer